The neonatal heel prick test, using dried blood spot (DBS) cards, is one of the most powerful tools in modern pediatric healthcare. Collected just days after birth, these tiny drops of blood have a lifelong impact, enabling early diagnosis, treatment, and long-term monitoring of a range of conditions.
In this article, we explore the most important use cases for neonatal DBS collection, from newborn screening to infection control and population research.
Shortly after birth, a healthcare provider performs a heel prick on a newborn to collect a few drops of blood. The blood is spotted onto a specially designed filter card, allowed to dry, and then sent to a laboratory for analysis. This process is quick, low-risk, and highly effective.
Once at the lab, the dried blood is analyzed for dozens of conditions using advanced techniques, including tandem mass spectrometry, PCR, and immunoassays.
The primary and most widespread use of neonatal dried blood spot collection is newborn screening. By testing for a panel of inherited disorders, these programs can detect serious, often life-threatening conditions before symptoms appear.
Commonly screened conditions include:
Early detection allows healthcare providers to intervene quickly, often preventing irreversible damage and significantly improving outcomes.
In certain settings, neonatal DBS samples are also used to screen for infections passed from mother to child during pregnancy or delivery. These include:
Dried blood spot analysis offers a convenient way to run serological and molecular tests from a single sample, making it ideal for comprehensive newborn evaluations.
Many countries retain DBS cards after screening is complete, with appropriate consent and privacy safeguards, for future use in research. These archived samples provide a unique, population-wide DNA resource for:
By analyzing archived neonatal DBS samples, researchers can track trends in disease, assess public health interventions, and uncover the genetic basis of childhood and adult illnesses.
Dried blood spot collection offers multiple benefits, particularly for newborns:
These features have made DBS the gold standard in newborn screening worldwide.
To maintain sample integrity and ensure reliable results, programs follow strict protocols:
Labs use automated punching and barcoding systems to reduce human error, and assays are validated to work effectively with the DBS matrix.
Neonatal DBS collection continues to revolutionize how we protect infant health. From preventing developmental delays to enabling cutting-edge research, these blood spots represent a starting point for a lifetime of better outcomes.
As technology advances and our understanding of genetics deepens, the use of DBS kits in newborn care will only expand, and RDA Spot remains committed to supporting this mission with high-quality materials and expertise.